Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Levi & Korsinsky Notifies Investors With Losses on Their Investment in Abiomed Inc of Class Action Lawsuit and Deadline of January 15, 2013 to Seek Lead Plaintiff Position


Tuesday, 8 Jan 2013 05:49pm EST 

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed Inc. The complaint alleges that, throughout the Class Period, Abiomed made materially misleading statements regarding the Company's financial strength and prospects. In particular, it is alleged that positive statements concerning the Company were misleading because the United States Food and Drug Administration (FDA) repeatedly warned Abiomed that its promotional materials contained inappropriate claims regarding its Impella 2.5 catheter and suggested improper off-label uses. Abiomed repeatedly assured investors that they had addressed the FDA's concerns and that the matter was resolved. 

Company Quote

24.25
0.15 +0.62%
12:42pm EDT